Pronova BioPharma ASA : Omacor and Zodin placed on negative reimbursement list in Greece

Lysaker, Norway, 11 January 2013: Pronova BioPharma (OSE: PRON.OL) has been informed that Omacor and Zodin have been placed on a negative reimbursement list in Greece as part of cost containment measures that is currently being implemented. The negative reimbursement list includes several hundred pharmaceutical products and was put in place in December. Pronova and its partners in Greece, Abbott Laboratories and Grupo Ferrer, have appealed the decision in order to secure continued good access to Omacor and Zodin for Greek patients. Greece is among the 8 largest markets for Pronova, and  represents around 4 percent of Pronova's total sales. Pronova has sales to 61 countries. Pronova BioPharma ASA Hamed Brodersen, VP Investor Relations and Communications Tel: +47 40 46 81 10 This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Pronova BioPharma ASA via Thomson Reuters ONE [HUG#1669759]